Cerebain Biotech Corp (CBBT) 0.9700 $CBBT
Cerebain Biotech and Mossakowski Medical Research Centre Sign Memorandum of Understanding
BusinessWire - Thu Jun 23, 7:30AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that they signed a Memorandum of Understanding with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the Memorandum of Understanding is to commence testing of Cerebain's Medical Device once development is completed.
Governor Scott McCallum, Representing Cerebain Biotech, to Present at US-Poland Health Care Summit
BusinessWire - Wed Jun 01, 7:25AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that Governor Scott McCallum, former governor of Wisconsin, has received an invitation and will be participating in a US-Poland Health Care Summit. The conference will begin on June 17, 2016 and be held in Warsaw, Poland.
CORRECTING and REPLACING Cerebain Biotech Today Announced It Plans to Seek FDA Approval
BusinessWire - Tue May 03, 3:09PM CDT
In fourth paragraph of release dated April 27, 2016, the former Governor of Wisconsin should read: Scott McCallum (instead of Scott Walker).
Cerebain Biotech Today Announced It Plans to Seek FDA Approval
BusinessWire - Wed Apr 27, 7:15AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company intends to seek FDA approval in conjunction with the development and testing of its medical device for the treatment of Alzheimer's and Dementia.
Cerebain Biotech Appoints Dr. Azad L. Sheikh to Scientific Advisory Board
BusinessWire - Mon Apr 11, 7:32AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Azad L. Sheikh, MBBS, MRCP (UK), FRCP (C), MBA, to its Scientific Advisory Board.
Cerebain Biotech Presents Corporate Update on Its War against Alzheimer's and Dementia
BusinessWire - Tue Nov 17, 9:48AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress made over the last year and an outlook of 2016.
Cerebain Biotech to sell up to 1.6m shares of its stock to GMEA
M2 - Tue Jun 09, 5:45AM CDT
Medical device company Cerebain Biotech (OTCBB:CBBT) disclosed on Monday that it has entered into an agreement to sell up to 1,600,000 shares of its stock to GMEA (Geronimo Middle East and Africa).
Cerebain Biotech Receives Financial Commitment of Two Million Dollars
BusinessWire - Mon Jun 08, 7:30AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company has executed an agreement with GMEA (Geronimo Middle East and Africa) to purchase up to One Million Six Hundred Thousand (1,600,000) shares of the company's stock. These funds will be used to support financial and business development goals that will help the company accelerate its research and testing programs, currently focused on the development of a new treatment in the fight against Alzheimer's Disease.
Cerebain Biotech Appoints Mustafa Husain, M.D., to Scientific Advisory Board
BusinessWire - Thu Jan 29, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Mustafa Husain, M.D., to its Scientific Advisory Board. Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.
Scott McCallum, Former Wisconsin Governor, Engaged by Cerebain Biotech as Special Advisor
BusinessWire - Thu Dec 04, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has engaged Scott McCallum, former governor of Wisconsin, entrepreneur and present Counsel on International Government to Hamilton Advisors, as a special advisor. Cerebain is an early-stage research and development company focused on evaluating a novel approach to the treatment of Alzheimer's Disease. Governor McCallum will serve as an invaluable resource in supporting rapid growth for the company as omental stimulation, the focus of Cerebain's research, is formally launched for study in Europe and then the United States.
Cerebain Biotech and Mossakowski Medical Research Centre Sign Memorandum of Understanding
BusinessWire - Thu Jun 23, 7:30AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that they signed a Memorandum of Understanding with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the Memorandum of Understanding is to commence testing of Cerebain's Medical Device once development is completed.
Governor Scott McCallum, Representing Cerebain Biotech, to Present at US-Poland Health Care Summit
BusinessWire - Wed Jun 01, 7:25AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that Governor Scott McCallum, former governor of Wisconsin, has received an invitation and will be participating in a US-Poland Health Care Summit. The conference will begin on June 17, 2016 and be held in Warsaw, Poland.
CORRECTING and REPLACING Cerebain Biotech Today Announced It Plans to Seek FDA Approval
BusinessWire - Tue May 03, 3:09PM CDT
In fourth paragraph of release dated April 27, 2016, the former Governor of Wisconsin should read: Scott McCallum (instead of Scott Walker).
Cerebain Biotech Today Announced It Plans to Seek FDA Approval
BusinessWire - Wed Apr 27, 7:15AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company intends to seek FDA approval in conjunction with the development and testing of its medical device for the treatment of Alzheimer's and Dementia.
Cerebain Biotech Appoints Dr. Azad L. Sheikh to Scientific Advisory Board
BusinessWire - Mon Apr 11, 7:32AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Azad L. Sheikh, MBBS, MRCP (UK), FRCP (C), MBA, to its Scientific Advisory Board.
Cerebain Biotech Presents Corporate Update on Its War against Alzheimer's and Dementia
BusinessWire - Tue Nov 17, 9:48AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress made over the last year and an outlook of 2016.
Cerebain Biotech to sell up to 1.6m shares of its stock to GMEA
M2 - Tue Jun 09, 5:45AM CDT
Medical device company Cerebain Biotech (OTCBB:CBBT) disclosed on Monday that it has entered into an agreement to sell up to 1,600,000 shares of its stock to GMEA (Geronimo Middle East and Africa).
Cerebain Biotech Receives Financial Commitment of Two Million Dollars
BusinessWire - Mon Jun 08, 7:30AM CDT
Cerebain Biotech (OTCQB: CBBT) today announced that the company has executed an agreement with GMEA (Geronimo Middle East and Africa) to purchase up to One Million Six Hundred Thousand (1,600,000) shares of the company's stock. These funds will be used to support financial and business development goals that will help the company accelerate its research and testing programs, currently focused on the development of a new treatment in the fight against Alzheimer's Disease.
Cerebain Biotech Appoints Mustafa Husain, M.D., to Scientific Advisory Board
BusinessWire - Thu Jan 29, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Mustafa Husain, M.D., to its Scientific Advisory Board. Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.
Scott McCallum, Former Wisconsin Governor, Engaged by Cerebain Biotech as Special Advisor
BusinessWire - Thu Dec 04, 6:30AM CST
Cerebain Biotech (OTCQB: CBBT) today announced that the company has engaged Scott McCallum, former governor of Wisconsin, entrepreneur and present Counsel on International Government to Hamilton Advisors, as a special advisor. Cerebain is an early-stage research and development company focused on evaluating a novel approach to the treatment of Alzheimer's Disease. Governor McCallum will serve as an invaluable resource in supporting rapid growth for the company as omental stimulation, the focus of Cerebain's research, is formally launched for study in Europe and then the United States.
